You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Estimated effectiveness of the pandemic influenza vaccine during the main wave of the influenza pandemic in Norway.

From: Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway

Week 45 46 47 48 49 50 51 52 53
Vaccinated population
No of cases 1 14 19 17 2 1 0 1 3
Population 32,766 266,278 501,115 698,006 873,629 1,105,763 1,397,506 1,675,354 1,891,980
Incidence(per 100,000) 3.05 5.26 3.79 2.44 0.23 0.09 0.00 0.06 0.16
Unvaccinated population
No of cases 2579 1612 866 453 187 84 34 16 12
Population 4,811,608 4,575,516 4,339,053 4,141,277 3,965,184 3,732,861 3,441,033 3,163,151 2,946,508
Incidence(per 100,000) 53.60 35.23 19.96 10.94 3.72 2.25 0.99 0.51 0.41
Vaccine effectiveness
Point estimate 94% 85% 81% 77% 95% 96% 100% 88% 61%
95% confidence interval 60%-99% 75%-90% 70%-88% 64%-86% 64%-99% 71%-99% - 11%-92% -37%-89%
  1. Estimated effectiveness of AS03-adjuvanted monovalent vaccine during the main wave (weeks 45-53, 2009) of the influenza pandemic in Norway Vaccinees were considered immune 15 days and later after vaccination.